Synthesis, characterization and application of Epichlorohydrin-β-cyclodextrin polymer

Colloids and Surfaces B: Biointerfaces

Volumn 114, Issue , 2014, Pages 130-137

  Gidwani, Bina ^a   Vyas, Amber ^a  

^a PT RAVISHANKAR SHUKLA UNIVERSITY   (India)

Author keywords

Drug delivery; Epichlorohydrin cyclodextrin; Host guest interaction; Hydrophilic; Polymerized cyclodextrin

Indexed keywords

BIOCHEMISTRY; CYCLODEXTRINS; DRUG DELIVERY; DRUG INTERACTIONS; GENE TRANSFER; INDUSTRIAL CHEMICALS; MOLECULAR WEIGHT; SOLUBILITY;

EPICHLOROHYDRIN; HIGH MOLECULAR WEIGHT COMPOUNDS; HOST GUEST INTERACTIONS; HYDROPHILIC; INFORMATION CONCERNING; ORAL BIOAVAILABILITIES; THERAPEUTIC EFFICIENCY; WATER-SOLUBLE DERIVATIVES;

FUNCTIONAL POLYMERS;

ACECLOFENAC; ACETOHEXAMIDE; BETA CYCLODEXTRIN; BUPIVACAINE; CINNARIZINE; DRUG CARRIER; EPICHLOROHYDRIN; EPICHLOROHYDRIN BETA CYCLODEXTRIN; FUROSEMIDE; GLIPIZIDE; INDOMETACIN; INSULIN; KETOPROFEN; POLYMER; TOLNAFTATE; TRICLOSAN; UNCLASSIFIED DRUG; WATER;

BIOMEDICINE; CARBOHYDRATE SYNTHESIS; CHEMICAL ANALYSIS; CHEMICAL INTERACTION; CHEMICAL MODIFICATION; CHEMICAL PROCEDURES; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; GENE DELIVERY SYSTEM; MOLECULAR WEIGHT; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SOLUBILITY; TOPICAL DRUG ADMINISTRATION;

DRUG DELIVERY; EPICHLOROHYDRIN-Β-CYCLODEXTRIN; HOST-GUEST INTERACTION; HYDROPHILIC; POLYMERIZED CYCLODEXTRIN;

BETA-CYCLODEXTRINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EPICHLOROHYDRIN; POLYMERS;

EID: 84887011549     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.09.035     Document Type: Review

References (90)

1. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. 2004, 52:900-915.
2. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85:1017-1025.
3. Szejtli J. Medicinal applications of cyclodextrins. Med. Res. Rev. 1994, 14:353-386.
4. Loftsson T., Fridriksdottir H., Sigurdardottir A.M. The effect of water-soluble polymers on drug-cyclodextrin complexation. Int. J. Pharm. 1994, 110:169-177.
5. Thompson D.O. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 1997, 14:1-104.
6. Ventura V.A., Tirendi S., Puglisi G., Bousquet E. Improvement of water solubility and dissolution rate of ursodeoxychilic acid and chenodeoxychilic acid by complexation with natural and modified cyclodextrins. Int. J. Pharm. 1997, 149:1-13.
7. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 1996, 85:1142-1169.
8. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 1997, 86:147-162.
9. Marcus E.B., Roger V., Peeters J., Peter N., Geert V., Thorsteinn L. Comparative interaction of 2-hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions. Eur. J. Pharm. Sci. 2008, 34:94-103.
10. Peeter J., Neeskens P., Adriaensen J., Brewster M. Effect of temperature on complexation with 2-hydroxypropyl-β-cyclodextrin. J. Incl. Phenom. Mol. 2002, 44:75-77.
11. Robert O., Vorapann M., Mongkol S. Characterization of an inclusion complex of cholesterol and hydroxypropyl-β-cyclodextrin. Eur. J. Pharm. Biopharm. 1998, 46:355-360.
12. Savolainen J., Jarvinun K., Matilainen L. Improved dissolution and bioavailability of phenytoin by sulfobutylether-cyclodextrin ((SBE) 7m-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) complexation. Int. J. Pharm. 1998, 165:69-78.
13. Szente L., Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 1999, 36:17-28.
14. Jose M.G., Carmen O.M., Jacques D. Glyconanocavities: cyclodextrins and beyond. J. Incl. Phenom. Macrocycl. Chem. 2006, 56:149-159.
15. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 2004, 3:1023-1035.
16. Singh M., Sharma R., Banerjee U.C. Biotechnological applications of cyclodextrins. Biotechnol. Rev. 2002, 5:341-359.
17. Easton C.J., Lincoln S.T. Modified Cyclodextrins, Scaffolds and Templates for Supramolecular Chemistry 1999, 1-226.
18. Uekama K., Hirayama F., Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 1998, 98:2045-2078.
19. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 1998, 98:1743-1753.
20. Szejtli J. Cyclodextrins and the molecular encapsulation. Chim. Oggi. 1987, 3:17-21.
21. Clarke R.J., Coates J.H., Lincoln S.F. Inclusion complexes of the cyclomalto-oligosaccharides (cyclodextrins). Adv. Carbohydr. Chem. Biochem. 1988, 46:205-249.
22. Connors K.A. The stability of cyclodextrin complexes in solution. Chem. Rev. 1997, 97:1325-1357.
23. Jiao H., Goh S.H., Valiyaveettil S. Inclusion complexes of single-C60-end-capped poly(ethylene oxide) with cyclodextrins. Macromolecules 2002, 35:1399-1402.
24. Oana M., Tintaru A., Gavriliu D., Maior O., Hillebrand M. Spectral study and molecular modeling of inclusion complexes of β-cyclodextrin with some phenoxathiine derivatives. J. Phys. Chem. 2002, 106:257-263.
25. Harada A. Preparation and structures of supramolecules between cyclodextrins and polymers. Coord. Chem. Rev. 1996, 148:115-133.
26. Yoshida K., Shimomura T., Ito K., Hayakawa R. Inclusion complex formation of cyclodextrin and polyaniline. Langmuir 1999, 15:910-913.
27. Harada A., Furue M., Nozakura S.I. Cyclodextrin-containing polymers. 1. Preparation of polymers. Macromolecules 1976, 9:701-704.
28. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 1996, 85:1142-1168.
29. Liu Y.Y., Fan X.D., Gao L. Synthesis and characterization of β-cyclodextrin based functional monomers and its copolymers with N-isopropylacrylamide. Macromol. Biosci. 2003, 3:715-719.
30. Crini G., Torri G., Guerini M., Martel B., Lekchiri Y., Morcellet M. Linear cyclodextrin-poly (vinylamine): synthesis and NMR characterization. Eur. Polym. J. 1997, 33:1143-1151.
31. Auzely-Velty R., Rinaudo M. Chitosan derivatives bearing pendant cyclodextrin cavities: synthesis and inclusion performance. Macromolecules 2001, 34:3574-3580.
32. Huh K.M., Tomita H., Lee W.K., Ooya T., Yui N. Synthesis of α-cyclodextrin-conjugated poly(epsiv-lysine)and their inclusion complexation behavior. Macromol. Rapid Commun. 2002, 23:179-182.
33. Guo X., Abdala A.A., May B.L., Lincoln S.F., Khan S.A. Novel associative polymer networks based on cyclodextrin inclusion compounds. Macromolecules 2005, 38:3037-3040.
34. Renard E., Volet G., Amiel C. Synthesis of a novel linear water-soluble β-cyclodextrin polymer. Polym. Int. 2005, 54:594-599.
35. Choi S.J., Geckeler K.E. A novel poly condensate containing cyclodextrin and lactose: synthesis, metal-complexing properties, and degradation. Polymer 2007, 48:1445-1449.
36. Renard E., Deratani A., Volet G. Preparation and characterization of water soluble high molecular weight β-cyclodextrin-epichlorohydrin polymers. Eur. Polym. J. 1997, 33:49-53.
37. Pariot N., Edwards-Levy F., Andry M.C. Cross-linked β-cyclodextrin microcapsules: preparation and properties. Int. J. Pharm. 2000, 211:19-27.
38. Garcia-Zubiria I.X., Gonzalez-Gaitanoa G., Isasi J.R. Isosteric heats of sorption of 1-naphthol and phenol from aqueous solutions by β-cyclodextrin polymers. J. Colloid Interface Sci. 2007, 307:64-70.
39. Volkova D.A., Bannikova G.E., Lopatin S.A., Gabinskaya K.N., Andryushina V.A., Gracheva I.M., Varlamov V.P. Effect of β-cyclodextrin-epichlorohydrin copolymer on the solubility of cortexolone. Pharm. Chem. J. 1999, 33:601-603.
40. Yu J.C., Jiang Z.T., Liu H.Y., Yu J., Zhang L. β-Cyclodextrin epichlorohydrin copolymer as a solid-phase extraction adsorbent for aromatic compounds in water samples. Anal. Chim. Acta 2003, 477:93-101.
41. Crini G., Bertini S., Torri G., Naggi A., Sforzini D., Vecchi C., Janus L., Lekchiri Y., Morcellet M. Sorption of aromatic compounds in water using insoluble cyclodextrin polymers. J. Appl. Polym. Sci. 1998, 68:1973-1978.
42. Romo A., Penas F.J., Isasi J.R. Sorption of dibenzofuran derivatives from aqueous solutions by β-cyclodextrin polymers: an isosteric heat approach. J. Colloid Interface Sci. 2004, 279:55-60.
43. Velaz I., Isasi J.R., Sanchez M., Uzqueda M., Ponchel G. Structural characteristics of some soluble and insoluble β-cyclodextrin polymers. J. Incl. Phenom. Macrocycl. Chem. 2007, 57:65-68.
44. Mocanu G., Vizitiu D., Carpov A. Cyclodextrins polymers. J. Bioact. Compat. Polym. 2001, 16:315-342.
45. Uekama K., Otagiri M., Irie T., Seo H., Tsuruoka M. Improvement of dissolution and absorption characteristics of phenytoin by a water-soluble cyclodextrin-epichlorohydrin polymer. Int. J. Pharm. 1985, 23:35-42.
46. Renard E., Barnathan G., Deratani A., Sebille B. Polycondensation of cyclodextrins with epichlorohydrin. Influence of reaction conditions on the polymer structure. Macromol. Symp. 1997, 122:229-234.
47. Fenyvesi E., Szilasi M., Zsadon B., Szejtli J., Tudo F. Water-soluble cyclodextrin polymers and their complexing properties. Proceedings of the First International Symposium on Cyclodextrins 1981, 345-356. Akademiai Kiado, Budapest. J. Szjetli (Ed.).
48. Szeman J., Ueda H., Szejtli J., Fenyvesi E., Machida Y., Nagai T. Complexation of several drugs with water-soluble cyclodextrin polymer. Chem. Pharm. Bull. 1987, 35:282-288.
49. Fenyvesi E. Cyclodextrin polymers in the pharmaceutical industry. J. Incl. Phenom. 1988, 6:537-545.
50. Wintgens V., Amiel C. Water-soluble γ-cyclodextrin polymers with high molecular weight and their complex forming properties. Eur. Polym. J. 2010, 46:1915-1922.
51. Crini N.M., Crini G. Environmental applications of water-insoluble β-cyclodextrin-epichlorohydrin polymers. Prog. Polym. Sci. 2013, 38:344-368.
52. Crini G., Morcellet M. Synthesis and applications of adsorbents containing cyclodextrins. J. Sep. Sci. 2002, 25:789-813.
53. Crini G., Peindy H. Adsorption of C.I. Basic Blue 9 on cyclodextrin-based material containing carboxylic groups. Dyes Pigment 2006, 70:204-211.
54. Duchene D. Cyclodextrin and Their Industrial Uses 1987, 448.
55. Mura P., Faucci M.T., Maestrelli F., Furlanetto S., Pinzauti S. Characterization of physicochemical properties of naproxen systems with amorphous beta-cyclodextrin-epichlorohydrin polymers. J. Pharm. Biomed. Anal. 2002, 29:1015-1024.
56. Deveswaran R., Puppala S.K.H., Bharath S., Basavaraj B.V., Madhavan V. Development of a novel water-soluble β-cyclodextrin epichlorohydrin polymer complex to improve aqueous solubility. J. Chem. Biol. Phys. Sci. 2012, 2:325-330.
57. Jug M., Maestrelli F., Bragagni M., Mura P. Preparation and solid-state characterization of bupivacaine hydrochloride cyclodextrin complexes aimed for buccal delivery. J. Pharm. Biomed. Anal. 2010, 52:9-18.
58. Pitha J., Mitchell Harman S., Michel M.E. Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones. J. Pharm. Sci. 1986, 75:165-167.
59. Nie S., Zhang S., Pan W., Liu Y. In vitro and in vivo studies on the complexes of glipizide with water-soluble β-cyclodextrin-epichlorohydrin polymers. Drug Dev. Ind. Pharm. 2011, 37:606-612.
60. Bhosale A.V., Hardikar S.R., Jagtap R.S., Patil N.B., Dhawale S.S., Shirsath S.C. Formulation of beta cyclodextrin complexed controlled release matrix tablet of glipizide and its in-vitro evaluation. Int. J. Pharm. Tech. Res. 2009, 1:773-778.
61. Rajan K., Verma S.G. Development and evaluation of osmotically controlled oral drug delivery system of glipizide. Eur. J. Pharm. Biopharm. 2004, 57:513-525.
62. Higuchi T., Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4:117-212.
63. Jug M., Kosalec I., Maestrelli F., Mura P. Analysis of triclosan inclusion complexes with β-cyclodextrin and its water-soluble polymeric derivative. J. Pharm. Biomed. Anal. 2011, 54:1030-1039.
64. Veiga M.D., Merino M., Cirri M., Maestrelli F., Mura P. Comparative study on triclosan interactions in solution and in the solid state with natural and chemically modified cyclodextrins. J. Incl. Phenom. Macrocycl. Chem. 2005, 53:77-83.
65. Stratul S.I., Onisei D., Rusu D. Antimicrobial agents in periodontal disease therapy: rationale and use of the triclosan PVM/MA copolymer in the management of gingivitis. Data from a consensus report. Part I TM. 59 2009, 105-108.
66. Layre A.M., Gosselet N.M., Renard E., Sebille B., Amiel C. Comparison of the complexation of cosmetical and pharmaceutical compounds with β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, and water soluble β-cyclodextrin-co-epichlorohydrin polymers. J. Incl. Phenom. Macrocycl. Chem. 2002, 43:311-317.
67. Stella V.J., Rajeswski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997, 14:556-567.
68. Malamed S.F. Local anesthetics: dentistry's most important drugs, clinical update. CDA J. 2006, 34:971-976.
69. Leone S., Di Cianni S., Cacati A., Fanelli G. Pharmacology, toxicology and clinical use of new long acting local anesthetics, ropivacaine and levobucaine. Acta Biomed. 2008, 79:92-105.
70. Golan D.E., Tashjian A.H., Armstrong E.J., Armstrong A.W. Local anesthetic pharmacology. Principles of Pharmacology 2008, Wolters Kluwer Health/Lippincott, Williams &Wilkins, Philadelphia. 2nd ed.
71. Nicolazzo J.A., Reed B.L., Finnin C. Buccal penetration enhancers - how they really work. J. Control. Release 2005, 105:1-15.
72. Brioschi A., Zenga F., Zara G.P., Gasco M.R., Ducati A., Mauro A. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors. Neurol. Res. 2007, 29:324-330.
73. Schafer-Korting M., Mehnert W., Korting H.C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev. 2007, 59:427-443.
74. Priano L., Esposti D., Esposti R., Castagna G., De Medici C., Fraschini F., Gasco M.R., Mauro A. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J. Nanosci. Nanotechnol. 2007, 7:3596-3601.
75. Mei Z., Chen H., Weng T., Yang Y., Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur. J. Pharm. Biopharm. 2003, 56:189-196.
76. Joshi M., Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int. J. Pharm. 2008, 346:124-132.
77. Puglia C., Blasi P., Rizza L., Schoubben A., Bonina F., Rossi C., Ricci M. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int. J. Pharm. 2008, 357:295-304.
78. Cirri M., Bragagni M., Mennini N., Mura P. Development of a new delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for ketoprofen topical delivery. Eur. J. Pharm. Biopharm. 2012, 80:46-53.
79. Rautio J., Nevalainen T., Taipale H., Vepsalainen J., Gynther J., Laine K., Jarvinen T. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur. J. Pharm. Sci. 2000, 11:157-163.
80. Bonina F., Puglia C., Barbuzzi T., De Caprariis P., Palagiano F., Rimoli M.G., Saija A. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur. J. Pharm. Sci. 2001, 14:123-134.
81. Maestrelli F., Gonzalez-Rodrìguez M.L., Rabasco A.M., Mura P. Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery. Int. J. Pharm. 2005, 298:55-67.
82. Nakai Y., Yamamoto K., Terada K., Akimoto K. The dispersed states of medicinal molecules in ground mixtures with α- or β-cyclodextrin. Chem. Pharm. Bull. 1984, 32:685-690.
83. Mura P., Bettinetti G.P., Manderioli A., Faucci M.T., Bramanti G., Sorrenti M. Interactions of ketoprofen and ibuprofen with β-cyclodextrins in solution and in the solid state. Int. J. Pharm. 1998, 166:189-203.
84. Mura P., Faucci M.T., Parrini P.L., Furlanetto S., Pinzauti S. Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems. Int. J. Pharm. 1999, 179:117-128.
85. Duchene D., Ponchel G., Wouassindjewe D. Cyclodextrins in targeting. Application to nanoparticles. Adv. Drug Deliv. Rev. 1999, 36:29-40.
86. McCormack B., Gregoriadis G. Drugs-in-cyclodextrins-in-liposomes: an approach to controlling the fate of water insoluble drugs in vivo. Int. J. Pharm. 1998, 162:59.
87. Cavalli R., Peira E., Caputo O., Gasco M.R. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Int. J. Pharm. 1998, 182:59-69.
88. Li J., Xiao H., Li J., Zhong Y. Drug carrier systems based on water soluble cationic beta-cyclodextrin polymers. Int. J. Pharm. 2004, 278:329-342.
89. Xin J., Guo Z., Chen X., Jiang W., Li J., Li M. Study of branched cationic β-cyclodextrin polymer/indomethacin complex and its release profile from alginate hydrogel. Int. J. Pharm. 2010, 386:221-228.
90. Zhang N., Li J., Jiang W., Ren C., Li J., Xin J., Li K. Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles. Int. J. Pharm. 2010, 393:212-218.